Title: |
Expert consensus on the immune checkpoint inhibitors treatment for recurrent/metastatic head and neck squamous cell carcinoma |
Edition: |
Original |
Classification: |
Experts consensus |
Field: |
Treatment |
Countries and regions: |
China |
Guidelines users: |
Chinese oncologists |
Evidence classification method: |
Oxford Centre for Evidence-Based Medicine |
Development unit: |
Head and Neck Cancer Committee of Chinese Society of Clinical Oncology |
Registration time: |
2023-04-19 |
Registration number: |
PREPARE-2023CN273 |
Purpose of the guideline: |
To guide the immunotherapy of reccurent/metastatic head and neck squamous cell carcinoma in China |